Background
==========

Gastric cancer (GC) is one of the most aggressively malignant tumors of the digestive tract. Most patients have been in advanced stage at diagnosis and the effectiveness of surgery is limited. Invasion and metastasis is the main cause of death in patients with gastric cancer. Among the potential promoting factors, tumor angiogenesis plays an important role \[[@b1-medscimonit-23-1286],[@b2-medscimonit-23-1286]\]. Tumor angiogenesis is the basis of tumor growth and metastasis. Therefore, it an important focus in the study of angiogenesis in gastric cancer and the search for new potential therapeutic targets.

Angiogenic factor with G-patch and FHA domain1 (AGGF1 or VG5Q), as a newly identified human angiogenic factor, was first reported by Tian et al. \[[@b3-medscimonit-23-1286]\] in 2004. The gene is highly expressed in vascular endothelial cells and the encoded protein has a strong angiogenesis ability *in vitro*. Recent studies have found that AGGF1 is expressed in some types of malignant tumors and is closely related to tumor angiogenesis \[[@b4-medscimonit-23-1286]--[@b7-medscimonit-23-1286]\]. Obviously, persistent angiogenesis, as one of the main signs of tumor, is closely related to the growth, invasion, metastasis, and recurrence of gastric cancer \[[@b1-medscimonit-23-1286],[@b2-medscimonit-23-1286]\], but the expression level of AGGF1 and its prognostic value in patients with gastric cancer have not been reported.

Therefore, in the present study, the protein expression levels of AGGF1 and vascular endothelial growth factor (VEGF) were examined by immunohistochemistry in GC and corresponding noncancerous samples. Next, Kaplan-Meier curves and log rank test were applied to analyze the survival rate. Lastly, Cox regression method was used to explore the prognostic value of AGGF1 in gastric cancer.

Material and Methods
====================

Patient and clinicopathologic data
----------------------------------

We selected specimens from 198 cases of gastric cancer (GC), along with the corresponding noncancerous tissues, from patients diagnosed at the Anhui Provincial Hospital of Anhui Medical University (Hefei, China) between 2007 and 2011. Detailed pathological and clinical data (including age, sex, tumor size, Borrmann type, degree of differentiation, histological type, metastasis of lymph node, invasion depth, and TNM staging) were obtained from each patient's medical records. The samples were obtained from 58 female and 140 male patients with an average age of 56±13 years old (range, 26--82 years). None of the patients had received radiotherapy or chemotherapy before surgery. The specimens were fixed in formalin and embedded in paraffin for pathological analysis and confirmation of the diagnosis. Complete clinical follow-up data was obtained from the gastric cancer database of our hospital. The study was approved by the Anhui Medical University Human Research Ethics Committee. Written informed consent was obtained from each patient.

Immunohistochemical study
-------------------------

Immunohistochemistry for AGGF1 and VEGF (both antibody concentrations were 1: 500) was performed on each cancerous and corresponding noncancerous tissue. The samples (4-μm thick) were cut onto salinized glass slides consecutively. Two-step immunohistochemistry was used to detect these proteins expression according to the manufacturer's instructions.

Every section was scored on the basis of the stained tumor cells fraction and staining intensity. The proportion was classified as 0 (≤1%), 1 (2% to 25%), 2 (26% to 50%), 2 (51% to 75%), and 4 (≥76%). The staining intensity was scored as 0 (no staining), 1 (weak), 2 (moderate), and 3 (strong). The expression result was calculated according to the formula: percentage score multiplied by intensity score. Total scores (0--12) were categorized as low (score 0--3) or high (score 4--12).

Statistical analysis
--------------------

SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses. Chi-square test and Spearman correlation test were used to analyze the immunohistochemical results. Kaplan-Meier and log rank test were applied to analyze the survival rates of patients. Cox regression method was used to determine the prognostic value. A *P*-value less than 0.05 was considered to indicate statistical significance.

Results
=======

AGGF1 expression in cancerous and noncancerous gastric tissues
--------------------------------------------------------------

In total, 198 paired cancerous and noncancerous tissue samples were analyzed by immunohistochemistry for AGGF1 expression. The AGGF1 immunoreactivity was mainly observed in the cytoplasm of neoplastic cells. High expression of AGGF1 was found in most cancer samples (132/198) and in fewer noncancerous samples (48/198). The expression level of AGGF1 in gastric cancer was dramatically higher than that in noncancerous samples (*P*\<0.001). Representative GC samples with different AGGF1 expression patterns are shown in [Figure 1](#f1-medscimonit-23-1286){ref-type="fig"}.

Correlation of AGGF1 with clinicopathological factors and VEGF
--------------------------------------------------------------

As shown in [Table 1](#t1-medscimonit-23-1286){ref-type="table"}, the expression of AGGF1 was remarkably associated with lymph node metastasis (P=0.022), invasion depth (P=0.006), and TNM stage (P\<0.001). Additionally, we also found there was a significantly positive correlation between VEGF and AGGF1 expression in gastric cancer samples (P=0.017, [Figure 2](#f2-medscimonit-23-1286){ref-type="fig"}).

Correlation of AGGF1 with patients' prognosis
---------------------------------------------

Kaplan-Meier method was plotted to compare the OS and DFS according to AGGF1 expression patterns. Patients with high-expression tumors showed a more unfavorable prognosis than those with low-expression tumors ([Figure 3](#f3-medscimonit-23-1286){ref-type="fig"}). Univariate survival analysis ([Tables 2](#t2-medscimonit-23-1286){ref-type="table"}, [3](#t3-medscimonit-23-1286){ref-type="table"}) revealed AGGF1 expression was remarkably associated with OS (P\<0.001) and DFS (P\<0.001), in addition to lymph node metastasis (P\<0.001 for OS, P \<0.001 for DFS), invasion depth (P=0.001 for OS, P\<0.001 for DFS), and TNM stage (P\<0.001 for OS, P\<0.001 for DFS). In multivariate analysis, lymph node metastasis (P=0.001 for OS, P=0.002 for DFS), invasion depth (P=0.024 for OS, P =0.024 for DFS), TNM stage (P\<0.001 for OS, P\<0.001 for DFS), and AGGF1 expression (P\<0.001 for OS, P\<0.001 for DFS) remained as independent factors ([Tables 4](#t4-medscimonit-23-1286){ref-type="table"}, [5](#t5-medscimonit-23-1286){ref-type="table"}).

Discussion
==========

Since the gene was first reported, AGGF1 and its physiological functions were further revealed, especially in the cardiovascular system. Chen et al. \[[@b8-medscimonit-23-1286]\] explored the function of AGGF1 in the angiogenesis of zebrafish and found that AGGF1 regulated the formation of blood vessels and the differentiation of veins. Lu et al. \[[@b9-medscimonit-23-1286]\] administered the angiogenic therapy in a mouse hindlimb ischemia model by using AGGF1 gene, which improved blood supply to the ischemic area. Another study found that AGGF1 inhibits vascular inflammatory response and improves endothelial function \[[@b10-medscimonit-23-1286]\]. Based on these findings, we speculate that AGGF1 plays an important role in the growth, metastasis, and invasion of gastric cancer. We found the expression level of AGGF1 protein was significantly higher in gastric cancer tissue than that in the corresponding noncancerous tissue. Similar to our results, a recent study found that hepatocellular carcinoma also displays overexpression of AGGF1 \[[@b7-medscimonit-23-1286]\]. Furthermore, patients with high AGGF1 expression had dramatically lower DFS and OS than those with low AGGF1 expression. Additionally, high AGGF1 expression in patients with gastric cancer was closely related to poor prognosis, as demonstrated by univariate and multivariate analyses.

Tumor angiogenesis plays a pivotal role in the progression and development of gastric cancer. Overexpression of VEGF is associated with unfavorable prognosis and aggressive behavior of tumors \[[@b11-medscimonit-23-1286]\]. Moreover, several studies have demonstrated that increased VEGF expression and microvessel density (MVD) are strongly related to worse prognosis in gastric cancer patients \[[@b12-medscimonit-23-1286]--[@b15-medscimonit-23-1286]\]. Therefore, to explore the role of AGGF1 in angiogenesis of gastric cancer, we explored the relationships between VEGF and AGGF1 expression levels in GC tissues. We also found a significantly positive relationship between AGGF1 and VEGF expressions in gastric cancer tissues, suggesting that AGGF1, probably cooperating with VEGF, is involved in tumor angiogenesis of gastric cancer. The potential underlying mechanisms may be that AGGF1 induces the expression of VEGF through β-catenin-dependent signaling \[[@b4-medscimonit-23-1286]\].

However, some limitations should be acknowledged in this study. Firstly, it was a retrospective study with relatively small samples. Secondly, we only used immunohistochemical method to examine the protein expression levels of AGGF1 and VEGF in gastric cancer tissues, and the gene expression level was not assessed. Lastly, the exact underlying mechanisms in the participation of AGGF1 in angiogenesis of gastric cancer need to be further explored.

Conclusions
===========

In summary, our preliminary results show that AGGF1 protein is overexpressed in gastric cancer tissues and it can be used as an independent parameter to evaluate and predict the postoperative survival time of gastric cancer patients. The potential mechanism is probably related to the promotion of tumor angiogenesis. In future, targeting AGGF1 for the inhibition of angiogenesis may be a new therapeutic strategy for gastric cancer patients.
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![Positive (**A**) and negative (**B**) expression of AGGF1 in gastric cancer and corresponding noncancerous tissues by immunohistochemistry, respectively (200× magnification).](medscimonit-23-1286-g001){#f1-medscimonit-23-1286}

![High expression levels of AGGF1 (**A**) and VEGF (**B**) in gastric cancer (200× magnification).](medscimonit-23-1286-g002){#f2-medscimonit-23-1286}

![Kaplan-Meier analysis of overall survival (OS) and disease-free survival (DFS) curves of patients with gastric cancer based on AGGF1 expression as positive or negative. (**A**) OS curve of patients with gastric cancer based on AGGF1 expression; (**B**) DFS curve of patients with gastric cancer based on AGGF1 expression.](medscimonit-23-1286-g003){#f3-medscimonit-23-1286}

###### 

Correlations between AGGF1 protein expressions and clinicopathological factors in patients with gastric cancer.

  variables                    Total   AGGF1 expression                  
  ---------------------------- ------- ------------------ ----- -------- -------
  Gender                                                                 
   Male                        140     44                 96    0.780    0.377
   Female                      58      22                 36             
  Age at surgery (yeas)                                                  
   ≤60                         94      35                 59    1.225    0.268
   \>60                        104     31                 73             
  Size of primary tumor (cm)                                             
   ≤5                          101     34                 67    0.010    0.920
   \>5                         97      32                 65             
  Borrmann type                                                          
   I+ II type                  67      23                 44    0.045    0.832
   III+IV type                 131     43                 88             
  Degree of differentiation                                              
   Well/moderate               85      30                 55    0.258    0.612
   Poor and not                113     36                 77             
  Histological type                                                      
   Adenocarcinoma              167     57                 110   0.306    0.580
   Others                      31      9                  22             
  Depth of invasion                                                      
   T1                          8       5                  3     12.388   0.006
   T2                          24      14                 10             
   T3                          62      20                 42             
   T4                          94      27                 77             
  Lymph node metastasis                                                  
   N0                          44      20                 24    9.602    0.022
   N1                          47      20                 27             
   N2                          56      16                 40             
   N3                          51      10                 41             
  TNM stage                                                              
   I                           13      9                  4     18.044   0.000
   II                          57      29                 34             
   III                         119     25                 83             
   IV                          9       3                  11             
  VEGF expression                                                        
   Low                         76      33                 43    5.648    0.017
   High                        122     33                 89             

###### 

Univariate analysis of the correlation between clinicopathological parameters and overall survival time of patients with gastric cancer.

  Variables                    Mean survival time (m)   95% CI           Log-rank test   *P* value
  ---------------------------- ------------------------ ---------------- --------------- -----------
  Gender                                                                                 
  Male                         45.013                   40.729--49.296   0.344           0.557
  Female                       42.637                   35.896--49.379                   
  Age at surgery (yeas)                                                                  
   ≤60                         45.585                   40.366--50.803   0.377           0.539
   \>60                        43.358                   38.348--48.367                   
  Size of primary tumor (cm)                                                             
   ≤5                          43.387                   38.485--48.289   0.236           0.627
   \>5                         45.577                   40.253--50.901                   
  Borrmann type                                                                          
   I+ II type                  46.035                   39.715--52.354   0.396           0.529
   III+IV type                 43.472                   39.063--47.881                   
  Degree of differentiation                                                              
   Well/moderate               48.339                   42.980--53.697   3.494           0.062
   Poor and not                41.237                   36.406--46.067                   
  Histological type                                                                      
   Adenocarcinoma              43.013                   39.097--46.930   2.770           0.096
   Others                      50.453                   41.753--59.153                   
  Depth of invasion                                                                      
   T1                          71.000                   69.303--72.697   16.372          0.001
   T2                          60.055                   51.567--68.544                   
   T3                          42.322                   35.986--48.657                   
   T4                          39.659                   34.737--44.580                   
  Lymph node metastasis                                                                  
   N0                          52.465                   45.378--59.551   21.639          0.000
   N1                          53.543                   46.738--60.348                   
   N2                          40.204                   33.820--46.588                   
   N3                          33.154                   26.253--40.056                   
  TNM stage                                                                              
   I                           71.200                   69.798--72.602   50.264          0.000
   II                          49.310                   43.488--55.132                   
   III                         41.309                   36.395--46.223                   
   IV                          16.698                   11.017--22.379                   
  AGGF1 expression                                                                       
   Low                         57.777                   53.817--62.737   22.538          0.000
   High                        37.830                   33.433--42.227                   

###### 

Univariate analysis of the correlation between clinicopathological parameters and disease free survival time of patients with gastric cancer.

  Variables                    Mean survival time (m)   95% CI           Log-rank test   *P* value
  ---------------------------- ------------------------ ---------------- --------------- -----------
  Gender                                                                                 
  Male                         42.455                   37.772--47.138   0.124           0.725
  Female                       40.506                   33.253--47.758                   
  Age at surgery (yeas)                                                                  
   ≤60                         43.372                   37.678--49.067   0.328           0.567
   \>60                        40.841                   35.408--46.274                   
  Size of primary tumor (cm)                                                             
   ≤5                          40.844                   35.509--46.179   .327            .567
   \>5                         43.252                   37.460--49.044                   
  Borrmann type                                                                          
   I+ II type                  43.836                   37.014--50.657   0.458           0.499
   III+IV type                 41.056                   36.244--45.869                   
  Degree of differentiation                                                              
   Well/moderate               45.897                   40.024--51.769   2.837           0.092
   Poor and not                41.237                   33.779--44.274                   
  Histological type                                                                      
   Adenocarcinoma              40.579                   36.340--44.818   2.430           0.119
   Others                      48.141                   38.375--57.907                   
  Depth of invasion                                                                      
   T1                          69.250                   64.582--73.918   16.505          0.001
   T2                          59.471                   50.651--68.290                   
   T3                          40.118                   33.162--47.074                   
   T4                          36.727                   31.346--42.108                   
  Lymph node metastasis                                                                  
   N0                          50.134                   42.355--57.914   19.960          0.000
   N1                          51.141                   43.721--58.561                   
   N2                          37.224                   30.221--44.228                   
   N3                          30.373                   22.813--37.934                   
  TNM stage                                                                              
   I                           70.429                   67.577--73.280   44.100          0.000
   II                          47.130                   40.785--53.474                   
   III                         38.787                   33.389--44.186                   
   IV                          12.800                   7.380--18.220                    
  AGGF1 expression                                                                       
   Low                         56.509                   51.135--61.882   23.489          0.000
   High                        34.898                   30.098--39.699                   

###### 

Multivariate analysis of the correlation between clinicopathological parameters and overall survival time of patients with gastric cancer.

  Covariates                                        HR      95% CI for HR   *P* value
  ------------------------------------------------- ------- --------------- -----------
  Gender (male *vs.* female)                        0.817   0.527--1.267    0.367
  Age (≥60 *vs.* \<60 cm)                           1.052   0.704--1.573    0.803
  Tumor size (≥5 *vs.* \<5 cm)                      1.031   0.679--1.566    0.886
  Borrmann type (type I, II *vs.* III, IV)          1.131   0.734--1.743    0.578
  Degree of differentiation                         0.877   0.584--1.318    0.528
  Histological type                                 1.539   0.822--2.882    0.178
  Depth of invasion (T3, T4 *vs.* T1, T2)           0.341   0.135--0.865    0.024
  Lymph node metastasis                             0.311   0.157--0.615    0.001
  TNM stage (stage I *vs.* II *vs.* III *vs.* IV)   0.161   0.079--0.331    0.000
  AGGF1 expression (low *vs.* high)                 0.354   0.213--0.586    0.000

###### 

Multivariate analysis of the correlation between clinicopathological parameters and disease free survival time of patients with gastric cancer.

  Covariates                                        HR      95% CI for HR   *P* value
  ------------------------------------------------- ------- --------------- -----------
  Gender (male *vs.* female)                        0.895   0.579--1.382    0.616
  Age (≥60 *vs.* \<60 cm)                           1.030   0.688--1.543    0.886
  Tumor size (≥5 *vs.* \<5 cm)                      1.045   0.689--1.586    0.836
  Borrmann type (type I, II *vs.* III, IV)          1.102   0.715--1.696    0.660
  Degree of differentiation                         0.909   0.605--1.364    0.644
  Histological type                                 1.483   0.792--2.778    0.218
  Depth of invasion (T3, T4 *vs.* T1, T2)           0.347   0.138--0.869    0.024
  Lymph node metastasis                             0.334   0.169--0.658    0.002
  TNM stage (stage I *vs.* II *vs.* III *vs.* IV)   0.196   0.096--0.401    0.000
  AGGF1 expression (low *vs.* high)                 0.366   0.222--0.604    0.000
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